# Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.

- **DOI:** [10.1002/clt2.70118](https://doi.org/10.1002/clt2.70118)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** Sebetralstat’s extension study expands evidence on oral treatment during mucosal HAE attacks, but its uncontrolled design cannot establish efficacy.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-02
- **Evaluation page:** https://www.nabu.science/paper/10.1002%2Fclt2.70118

## Key claims

1. The KONFIDENT‐S OLE demonstrates that sebetralstat is a safe and effective oral on‐demand treatment for both laryngeal and abdominal HAE‐C1INH attacks, resulting in rapid onset of symptom relief.
   - Support: Tentative
   - Type: Primary finding
   - Basis: the uncontrolled open-label design cannot attribute observed symptom relief to sebetralstat
   - Location: Conclusions
2. No participants reported difficulty swallowing sebetralstat during laryngeal or abdominal attacks.
   - Support: Supported
   - Type: Secondary
   - Basis: an observed feasibility finding limited by unspecified collection methods and few severe laryngeal attacks
   - Location: Results, Safety and Tolerability
3. Most of the attacks affecting the larynx (96.0%) and abdominal attacks (95.8%) that achieved beginning of symptom relief within 12 h did so with a single dose of sebetralstat.
   - Support: Supported
   - Type: Secondary
   - Basis: a descriptive result conditional on observed relief within 12 hours, without a controlled estimate of single-dose efficacy
   - Location: Results, Effectiveness
4. Seven (43.8%) participants with laryngeal attacks experienced 14 TEAEs whereas 36 (35.3%) participants with abdominal attacks experienced 91 TEAEs.
   - Support: Supported
   - Type: Secondary
   - Basis: descriptive participant-level counts without clear attack-linked attribution or exposure-adjusted rates
   - Location: Abstract; Results, Safety and Tolerability

## Strengths

- **Expanded prospective evidence for mucosal attacks** The analysis includes 32 laryngeal and 533 abdominal attacks, expanding the earlier interim dataset and addressing documented concerns about oral administration during mucosal swelling.
  - Dimension: contribution
  - Location: Introduction, final paragraphs; Results, Attack Characteristics
- **Defined endpoints and scheduled electronic diaries** The prespecified interim analysis defines symptom-relief, severity-reduction, and resolution endpoints and specifies electronic-diary assessment intervals. Post hoc outcomes are explicitly identified.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Study Endpoints
- **Prior evidence and comparison limits addressed** The Introduction situates the analysis against randomized trials and concerns about oral dosing. The Discussion explains how population, severity, and endpoint differences restrict comparisons with injectable therapies.
  - Dimension: positioning
  - Location: Introduction; Discussion, cross-study comparisons

## Limitations

- **Uncontrolled observations cannot establish treatment efficacy** The extension lacks a concurrent comparator, while symptom outcomes are participant-reported. Its conclusion that treatment effectiveness is demonstrated exceeds what the observed trajectories identify.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Statistics; Discussion, final paragraph; Conclusions
- **Adverse event collection method remains unspecified** Safety is the primary outcome, but the Methods does not explain how adverse events were systematically elicited. Event counts, grades, serious events, and discontinuations are reported without resolving that collection-method gap.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Study Endpoints; Results, Safety and Tolerability
- **Laryngeal evidence rests on few participants** Only 16 participants contributed 32 laryngeal attacks, with locations reported without clinical confirmation. This limits extrapolation to broader and severe laryngeal presentations.
  - Dimension: application pathway
  - Location: Results, Participants and Attack Characteristics; Discussion, final paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. The supplied main text does not declare ethics approval or the consent process for the interventional study, which included adolescents. Trial registration, funding, conflicts of interest, and restricted data availability are disclosed.
  - Conflict of interest: declared · Ethics approval: not stated · Preregistration: declared · Data availability: declared
- **Reference integrity:** Clean
  - 33 references in manuscript
  - 30 of 30 checkable references found in an index
  - 3 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-02
